Astellas Announces a Collaboration With YASKAWA to Create an Innovative Cell Therapy Ecosystem Through the Integration of Pharmaceutical and Robotics Technologies
Astellas Announces a Collaboration With YASKAWA to Create an Innovative Cell Therapy Ecosystem Through the Integration of Pharmaceutical and Robotics Technologies
- Focuses on digitizing cell manufacturing processes through robotics technology
-專注於通過機器人技術實現電池製造過程的數字化
TOKYO, May 21, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it signed a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA) to begin discussions on the creation of an innovative cell therapy ecosystem through the integration of pharmaceutical and robotics technologies. This memorandum is legally non-binding and will lead to further specific discussions between the two companies in the future.
東京，2024年5月21日 /PRNewswire/ — 安斯泰來製藥公司（東京證券交易所：4503，總裁兼首席執行官：岡村直樹，“安斯泰來”）今天宣佈，它與安川電機公司（YASKAWA）簽署了諒解備忘錄，開始討論通過整合製藥和機器人技術來創建創新的細胞療法生態系統。該備忘錄不具有法律約束力，將導致兩家公司將來進行進一步的具體討論。
The complexity of product manufacturing is a significant challenge to commercializing cell therapy. Substantial investments are required to develop complex manufacturing processes, transfer technology among manufacturers, and establish large-scale manufacturing facilities for commercialization. This makes it difficult for startups and academia to commercialize cell therapy independently.
產品製造的複雜性是細胞療法商業化面臨的重大挑戰。開發複雜的製造工藝、在製造商之間轉讓技術以及建立大規模的商業化製造設施需要大量投資。這使得初創企業和學術界難以獨立地將細胞療法商業化。
Since the end of 2017, Astellas has been advancing drug discovery and manufacturing technology research in cell therapy through the introduction of the humanoid robot "Maholo", developed by the Robotic Biology Institute, a subsidiary of YASKAWA.
自2017年底以來，安斯泰來通過引入由安川子公司機器人生物學研究所開發的仿人機器人 “Maholo”，一直在推進細胞療法領域的藥物發現和製造技術研究。
Under the terms of the memorandum, the companies will begin discussions to potentially develop a platform that may seamlessly link early-stage research to commercialization, utilizing the state-of-the-art Maholo robot to manufacture high-quality products and shorten the R&D period of cell therapy.
根據備忘錄的條款，兩家公司將開始討論可能開發一個平台，該平台可以將早期研究與商業化無縫聯繫起來，利用最先進的Maholo機器人來製造高質量的產品並縮短細胞療法的研發週期。
Furthermore, the companies would consider the possibility of potentially offering the use of the platform to startups and academia, aiming to develop an advanced cell therapy ecosystem that may enable the discovery and nurturing of innovation while potentially reducing investment in investigational drug manufacturing based on the Pharmaceutical and Medical Device Act*1.
此外，兩家公司將考慮是否有可能向初創企業和學術界提供該平台的使用權，旨在開發先進的細胞療法生態系統，從而能夠發現和培育創新，同時有可能減少對基於《製藥和醫療器械法》的研究藥物製造的投資*1。
Astellas would provide cell manufacturing technology, clinical development and regulatory insights related to cell therapy. YASKAWA would provide and develop state-of-the-art robotics and factory automation technologies.
安斯泰來將提供與細胞療法相關的細胞製造技術、臨床開發和監管見解。YASKAWA將提供和開發最先進的機器人和工廠自動化技術。
Astellas is committed to achieving our VISION of being "on the forefront of healthcare change, turning innovative science into VALUE for patients". With this potential partnership, Astellas would further contribute to startups and academia working on cell therapy to deliver cutting-edge cell therapy products with the potential to be innovative treatments to patients.
安斯泰來致力於實現我們的願景，即 “站在醫療變革的最前沿，將創新科學轉化爲患者的價值”。通過這種潛在的合作伙伴關係，安斯泰來將進一步爲從事細胞療法的初創企業和學術界做出貢獻，爲患者提供有可能成爲創新療法的尖端細胞療法產品。
The impact of this memorandum on Astellas' financial results for the fiscal year ending March 31, 2025, is expected to be minor.
預計該備忘錄對安斯泰來截至2025年3月31日的財年財務業績的影響微乎其微。
YASKAWA announces "Yaskawa Partners with Astellas Pharma on Building a Cell Therapy Platform Combining Robotics and Pharmaceutical Technologies" on the same day.
安川在同一天宣佈 “安川與安斯泰來製藥合作構建結合機器人和製藥技術的細胞治療平台”。
*1 Pharmaceutical and Medical Device Act: Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices
*1 《藥品和醫療器械法》：《確保藥品和醫療器械等產品的質量、有效性和安全性法》
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+ healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at
關於安斯泰來
安斯泰來製藥公司是一家在全球70多個國家開展業務的製藥公司。我們正在推廣重點領域方法，該方法旨在尋找機會，通過專注於生物學和模態學來持續開發新藥，以解決醫療需求未得到滿足的嚴重疾病。此外，我們還將目光投向了基本 Rx 重點之外，創建 Rx+ 醫療保健解決方案，將我們的專業知識與外部合作伙伴不同領域的尖端技術相結合。通過這些努力，安斯泰來站在醫療變革的最前沿，將創新科學轉化爲患者的價值。欲了解更多信息，請訪問我們的網站
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
警示說明
在本新聞稿中，有關當前計劃、估計、戰略和信念的聲明以及其他非歷史事實的陳述是關於安斯泰來未來業績的前瞻性陳述。這些陳述基於管理層根據目前可用的信息作出的當前假設和信念，涉及已知和未知的風險和不確定性。許多因素可能導致實際結果與前瞻性陳述中討論的結果存在重大差異。這些因素包括但不限於：（i）總體經濟狀況以及與藥品市場有關的法律法規的變化，（ii）貨幣匯率波動，（iii）新產品發佈的延遲，（iv）安斯泰來無法有效銷售現有和新產品，（v）安斯泰來無法繼續有效研究和開發在競爭激烈的市場中被客戶接受的產品，以及（vi）侵權第三方擁有的安斯泰來知識產權。
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
本新聞稿中包含的有關醫藥產品（包括正在開發的產品）的信息無意構成廣告或醫療建議。
SOURCE Astellas Pharma Inc.
來源 Astellas Pharma Inc.
譯文內容由第三人軟體翻譯。